Environmental, Health & Safety (EHS) considerations are an integrated part of our every day work. Our main concerns include reducing our consumption of resources, such as water, energy and chemicals, and reducing atmospheric emissions from the production process, and also preventing any contact with chemicals.
Our dedicated EHS department encourages the environmental, health and safety consciousness of our staff, by ensuring that each member has the necessary skills and knowledge to minimise environmental impact and secure a healthy and safe environment while on the job.
We are committed to having net zero emissions across our entire value chain by 2045, which is anchored in our zero environmental impact strategy called Circular for Zero.
As 2045 approaches, we have an interim target to reach zero CO2 emissions from own operation and transport by 2030 – an important milestone in achieving our greater net zero commitment.
In 2018 we achieved our goal of sourcing 100% renewable electricity and our next step is to transform our business processes to eliminate the environmental footprint from our operation.
We are DS/EN ISO 14001 as well as DS/EN ISO 45001 certified.
At Novo Nordisk Pharmatech we develop, manufacture, and deliver products and services to the pharmaceutical and biopharmaceutical industry. We export our products worldwide, and Novo Nordisk A/S uses some of our products in the manufacturing process of Novo Nordisk products.
Environmental sustainability at Novo Nordisk Pharmatech entails a commitment to minimize the effect our operation has on our surrounding environment. We consider the following to be our most significant environmental impacts across our value chain:
Novo Nordisk Pharmatech integratse environmental considerations into everything we do and is committed to our environmental strategy of having zero environmental impact by embedding circular economy in our business. We work across our entire value chain. This means we will:
Our Executive Management is responsible for the overall environmental policy and for setting strategic direction within the environmental area. We ensure clear communication on our policy and strategic direction, both internally and externally, and ensure to report progress in a timely and transparent way.
At Novo Nordisk Pharmatech we develop, manufacture, and deliver products and services to the pharmaceutical and biopharmaceutical industry. We export our products worldwide, and Novo Nordisk A/S uses some of our products in the manufacturing process of Novo Nordisk products.
Health and safety contribute to Novo Nordisk Pharmatech sustainability by proactively identifying and mitigating for our significant aspects (process risk/emergency management, chemical and hazardous materials, ergonomics, falls and transport). We are committed to:
At Novo Nordisk Pharmatech prevention and continual improvement is the key to our health and safety management system and site culture. We are committed to uphold a safe and healthy working environment, that is an attractive and modern workplace which promotes the health and wellbeing of those who work at our facilities. This means we will:
Our Executive Management is responsible for the overall health and safety policy and for setting the strategic direction within this area. We ensure clear communication on our policy and strategic direction, both internally and externally, and ensure to report progress in a timely and transparent way.
Novo Nordisk Pharmatech has worked intensively to improve and maintain a sustainable approach to the well-being of our employees.
In the past few years, Novo Nordisk Pharmatech has performed yearly training of managers and employees in preventing stress and maintaining well-being, implemented dialogue-based assessment of stress symptoms and continuous follow up.
Fighting sedentary work
To fight the risk of sedentary work Novo Nordisk Pharmatech has implemented the Novo Nordisk way of doing Power Brakes: NovoGizers.
Novo Nordisk Pharmatech promotes this to be done up til twice a day & NovoGizer Captains with this interest are being offered training and new inputs to keep the NovoGizers in focus and up to date.
In terms of absence due to illness, we have in 2022 continued the intensive work we initiated in 2019, where employees with complex long-term illnesses were supported with back-to-work plans and/or best possible alternative solutions in close collaboration with local municipalities, medical doctors and Novo Nordisk social counsellors. Throughout the last couple of years, we have manage to maintain a low level of absence due to illness around 3,3%
We have changed our performance-management approach to focus on behaviour through continuous dialogue and feedback between manager and employee. Behavioural targets are designed from the Novo Nordisk Way and our Novo Nordisk Pharmatech United Culture, which has particular emphasis on strengthening our commercial mindset, our focus on simplicity and our ability to collaborate across departments
As a Novo Nordisk company, we work with the “Triple Bottom Line” principle, the CO2 Reduction program, and follow Novo Nordisk’s People Policy.
We strive to conduct our activities in a financially, environmentally and socially responsible way. This implies that any decision should always seek to balance three considerations:
This principle ensures that decision-making balances financial growth with corporate responsibility, short-term gains with long-term profitability and shareholder return with other stakeholder interests.
Novo Nordisk Pharmatech is committed to having net zero emissions across our entire value chain by 2045, which is anchored in Novo Nordisk’s zero environmental impact strategy called Circular for Zero. As 2045 approaches, we have an interim target of having zero CO2 emissions from own operation and transportation by 2030. In 2018 we achieved our goal of sourcing 100% renewable electricity and our next step is to transform our business processes to eliminate the environmental footprint from our operation, which we due by carrying out awareness and idea-generating workshops and by establishing local Circular for Zero targets with rolling 5 years targets.
In 2020, Novo Nordisk Pharmatech has mapped our own and our suppliers’ CO2 emissions. The CO2 emissions are followed closely. By 2030, Novo Nordisk Pharmatech will require that all of our supply must be based on 100% renewable power. Our Circular for Zero strategy challenges us to find new ways of doing things and to reshape our business to minimize consumption and waste. This has for example resulted in establishing electrical car-charging stations and having company owned electrical bikes, to give our employees sustainable commuting options. We have also replaced gas furnaces for heating with electrical heat pumps and installed solar panels on our Administration Building.
Read more about Novo Nordisk’s journey.
We are proud of this acknowledgement on our sustainability efforts and will continue the journey of being a trusted sustainable business partner.
Novo Nordisk Pharmatech has been recognized as one of the top 1% of companies assessed for the EcoVadis Sustainability Assessment Report. This report is considered the most trusted business sustainability rating in the world, with over 100,000 rated companies across 175+ countries and 200+ industries. Novo Nordisk Pharmatech’s performance in areas such as Environment, Labour & Human Rights, Ethics, and Sustainable Procurement was evaluated, and the company was awarded the Platinum Medal for its sustainable practices.
In 2022 Novo Nordisk Pharmatech has been included among the top 1% of companies assessed for the EcoVadis Sustainability Assessment Report. EcoVadis has the past 15 years created an extensive global network that they guide toward a more sustainable world.